Abstract | BACKGROUND:
Tasisulam sodium (hereafter tasisulam), a novel anticancer agent, is being studied in a broad range of tumors. The primary objective of this phase II study was to determine progression-free survival (PFS) in patients with 1 or 2 prior chemotherapy regimens for unresectable/metastatic soft tissue sarcoma (STS). Secondary objectives included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), pharmacokinetics, and safety. METHODS:
Tasisulam was administered intravenously on day 1 of 21-day cycles according to a lean body weight-based dosing algorithm targeting a peak plasma concentration (C(max)) of 420 μg/mL; a 360-μg/mL dose level was also explored. RESULTS: The median age of patients treated at 420 μg/mL was 58.3 years (range, 18.6-80.4; n = 63). Median PFS was 2.64 months (90 % CI, 1.41-3.38), with a 6-month PFS rate of 11 % (90 % CI, 4-17). Median OS was 8.71 months (90 % CI, 7.39-16.23); ORR, 3.2 %; and CBR, 46.0 % (stable disease, n = 27; partial response/confirmed, n = 2 [ angiosarcoma and leiomyosarcoma]; partial response/unconfirmed, n = 1 [ desmoplastic small round cell tumor]). The most frequent drug-related grade 3/4 toxicities in patients treated at 420 μg/mL were thrombocytopenia (27.0 %) and neutropenia (22.2 %). Incidences of grade 4 thrombocytopenia and/or neutropenia were 20.6 % in patients treated at 420 μg/mL and 15.8 % in those treated at 360 μg/mL (n = 38). CONCLUSIONS:
Tasisulam at a target C(max) of 420 μg/mL on day 1 of 21-day cycles demonstrated modest activity as second-/third-line treatment in patients with STS. Grade 4 hematologic toxicity posed some challenges in these heavily pre-treated patients. Tasisulam dosing continues to be refined.
|
Authors | Christopher W Ryan, Chacon Matias, Mark Agulnik, Antonio Lopez-Pousa, Charles Williams, Dinesh P de Alwis, Christopher Kaiser, Mary Alice Miller, Sabine Ermisch, Robert Ilaria Jr, M L Keohan |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 31
Issue 1
Pg. 145-51
(Feb 2013)
ISSN: 1573-0646 [Electronic] United States |
PMID | 22539091
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide
- Sulfonamides
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(pharmacokinetics, therapeutic use)
- Benzamides
(pharmacokinetics, therapeutic use)
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Sarcoma
(blood, drug therapy)
- Sulfonamides
(pharmacokinetics, therapeutic use)
- Young Adult
|